(7), in the present study, we noted no direct clinical benefit to extending the RET germline analysis beyond the hot-spot regions in patients with sporadic MTC with multifocality (22%) since the analysis did not identify any mutations in other exons. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.